SCHEMBL6487994

SCHEMBL6487994

Cc1cc2cc(NC(=O)C3CC3)ccc2n1C(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
JAK2 O60674 2/20 0.45
JAK1 P23458 2/20 0.45
TYK2 P29597 2/20 0.45
CDK9 P50750 1/20 0.45
JAK3 P52333 1/20 0.45
UBE2M P61081 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
MALT1 Q9UDY8 2/20 0.43
MGLL Q99685 1/20 0.43
GNRHR P30968 1/20 0.43
MAPT P10636 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492262 0.96 NPSR1 (0.47) KMT2AHPGDSMN1; SMN2JAK2JAK1
SCHEMBL6480891 0.96 NPSR1 (0.50) LMNAHPGDSMN1; SMN2JAK2JAK1
SCHEMBL6481059 0.95 NPSR1 (0.49) LMNAHPGDSMN1; SMN2JAK2TYK2
SCHEMBL6490688 0.93 MGLL (0.44) MEN1KMT2ALMNAHPGDALOX15
SCHEMBL6489189 0.90 HSD17B10 (0.46) MEN1KMT2ALMNAHPGDHTT
SCHEMBL6489974 0.89 JAK2 (0.43) KMT2ASMN1; SMN2JAK2JAK1TYK2
SCHEMBL6492402 0.89 NPSR1 (0.46) HPGDSMN1; SMN2JAK2JAK1TYK2
SCHEMBL6492666 0.88 NPSR1 (0.45) HPGDSMN1; SMN2JAK2TYK2NPSR1
SCHEMBL6489116 0.88 HSD17B10 (0.44) MEN1KMT2ALMNAHPGDHTT
SCHEMBL6480576 0.86 MTNR1A (0.47) HPGDHTTJAK1NPSR1MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 MEN1 4842/4885KMT2A 3232/4885LMNA 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.